KZIA Initiates Coverage On by Canaccord Genuity -- Price Target Announced at $29
Canaccord Genuity has initiated coverage on Kazia Therapeutics (KZIA) with a 'Buy' rating and a price target of $29.00, significantly higher than its current market price of $13.09. Despite this positive analyst outlook and strong momentum, the company holds a low GF Score™ of …